Goldman Sachs initiated coverage of Sotera Health (SHC) with a Neutral rating and $14 price target representing upside potential of 8%. Sotera is a mature, commercial stage medical technology company that provides sterilization and lab testing services as an essential component of the manufacturing process for its customers, the analyst tells investors in a research note. The firm is cautious on potential litigation risk within the company’s sterilization facilities, noting it faces a number of ongoing cases.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue